Search research articles
Contact Us
Filters
Showing results (201-210 of 238) with videos related to
Page
of 24
Sort By:
British Journal of Clinical Pharmacology
|
August 24, 2022
Multiple-ascending doses of ACT-1014-6470, an oral complement factor 5a receptor 1 (C5a<sub>1</sub> receptor) antagonist: Tolerability, pharmacokinetics and target engagement
Marion Anliker-Ort, Jasper Dingemanse, Hervé Farine, et al.
Journal of Cardiovascular Pharmacology
|
October 16, 2013
Tolerability and pharmacokinetics of ACT-280778, a novel nondihydropyridine dual L/T-type calcium channel blocker: early clinical studies in healthy male subjects using adaptive designs
Markus S Mueller, Kasra Shakeri-Nejad, Marcelo M Gutierrez, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
February 23, 2013
Elucidation of the metabolic pathways and the resulting multiple metabolites of almorexant, a dual orexin receptor antagonist, in humans
Jasper Dingemanse, Petra Hoever, Matthias Hoch, et al.
Clinical Pharmacology and Therapeutics
|
July 13, 2017
Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement
Nicolas Guérard, Daniel Oder, Peter Nordbeck, et al.
The AAPS Journal
|
December 23, 2011
Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist
Shirin Bruderer, Päivi Aänismaa, Marie-Claude Homery, et al.
Journal of Clinical Pharmacology
|
February 7, 2015
A novel CRTH2 antagonist: Single- and multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ACT-453859 in healthy subjects
Martine Géhin, Daniel S Strasser, Jochen Zisowsky, et al.
Pharmacology Research & Perspectives
|
July 20, 2023
Modeling time-delayed concentration-QT effects with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5a<sub>1</sub> receptor) antagonist
Marion Anliker-Ort, Chih-Hsuan Hsin, Andreas Krause, et al.
British Journal of Clinical Pharmacology
|
September 27, 2023
Pharmacokinetics, pharmacodynamics and safety of the novel C-X-C chemokine receptor 3 antagonist ACT-777991: Results from the first-in-human study in healthy adults
Marie-Laure Boof, Martine Géhin, Christine Voors-Pette, et al.
Clinical Pharmacokinetics
|
December 23, 2015
Pharmacokinetic/Pharmacodynamic Modelling of Receptor Internalization with CRTH2 Antagonists to Optimize Dose Selection
Andreas Krause, Jochen Zisowsky, Daniel S Strasser, et al.
Scientific Reports
|
March 12, 2020
Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development
Lydia Burgert, Matthias Rottmann, Sergio Wittlin, et al.
Page
of 24
Search research articles
Search
Showing results (201-210 of 238) with videos related to
Sort By:
Page
of 24
British Journal of Clinical Pharmacology
|
August 24, 2022
Multiple-ascending doses of ACT-1014-6470, an oral complement factor 5a receptor 1 (C5a<sub>1</sub> receptor) antagonist: Tolerability, pharmacokinetics and target engagement
Marion Anliker-Ort, Jasper Dingemanse, Hervé Farine, et al.
Journal of Cardiovascular Pharmacology
|
October 16, 2013
Tolerability and pharmacokinetics of ACT-280778, a novel nondihydropyridine dual L/T-type calcium channel blocker: early clinical studies in healthy male subjects using adaptive designs
Markus S Mueller, Kasra Shakeri-Nejad, Marcelo M Gutierrez, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
February 23, 2013
Elucidation of the metabolic pathways and the resulting multiple metabolites of almorexant, a dual orexin receptor antagonist, in humans
Jasper Dingemanse, Petra Hoever, Matthias Hoch, et al.
Clinical Pharmacology and Therapeutics
|
July 13, 2017
Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement
Nicolas Guérard, Daniel Oder, Peter Nordbeck, et al.
The AAPS Journal
|
December 23, 2011
Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist
Shirin Bruderer, Päivi Aänismaa, Marie-Claude Homery, et al.
Journal of Clinical Pharmacology
|
February 7, 2015
A novel CRTH2 antagonist: Single- and multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ACT-453859 in healthy subjects
Martine Géhin, Daniel S Strasser, Jochen Zisowsky, et al.
Pharmacology Research & Perspectives
|
July 20, 2023
Modeling time-delayed concentration-QT effects with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5a<sub>1</sub> receptor) antagonist
Marion Anliker-Ort, Chih-Hsuan Hsin, Andreas Krause, et al.
British Journal of Clinical Pharmacology
|
September 27, 2023
Pharmacokinetics, pharmacodynamics and safety of the novel C-X-C chemokine receptor 3 antagonist ACT-777991: Results from the first-in-human study in healthy adults
Marie-Laure Boof, Martine Géhin, Christine Voors-Pette, et al.
Clinical Pharmacokinetics
|
December 23, 2015
Pharmacokinetic/Pharmacodynamic Modelling of Receptor Internalization with CRTH2 Antagonists to Optimize Dose Selection
Andreas Krause, Jochen Zisowsky, Daniel S Strasser, et al.
Scientific Reports
|
March 12, 2020
Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development
Lydia Burgert, Matthias Rottmann, Sergio Wittlin, et al.
Page
of 24